About the Webinar
Translocations and other structural variants (SV) are common in patients with B-cell acute lymphoblastic leukemia (B-ALL). Identification of the specific SV present within a patient sample can inform patient prognosis as well as guide patient treatment, but existing testing is often painful and invasive. Here, we demonstrate how Hi-C sequencing serves as a viable alternative to current clinical tests based on fluorescence in situ hybridization (FISH) assays.
Key Takeaways
- Learn how analysis of shallow-depth Hi-C sequencing may be a cost-effective alternative to FISH-based SV detection
- Learn how 3D genomic approaches can detect novel SVs among B-ALL patients that may be missed by the standard candidate-based testing
- Learn how SV detection sensitivity with Hi-C is sufficient to allow testing from peripheral blood rather than blood marrow, which reduces invasiveness and discomfort for the patient
Meet the Speakers
Michael Johnston, PhD
Postdoctoral Fellow, University of CalgaryMichael is a postdoctoral fellow in the Gallo Lab within the Arnie Charbonneau Cancer Institute at the University of Calgary. His research aims to identify alterations to the non-protein-coding genome that drive tumorigenesis, using combinations of both genetic and epigenetic sequencing strategies. His postdoctoral studies have applied Hi-C to study both adult and pediatric brain tumors, as well as leukemia.
Pamela Bentley Mills, PhD
Director, Scientific Content + CommunicationsPamela leads content strategy and creation at Arima Genomics to educate and engage the scientific community on the power of 3D genomics to drive discovery and improve human health. Pamela received her PhD from the University of Alberta where she worked on elucidating the effects of photoperiod and circadian rhythms on mammary gland development, function, and transcriptional regulation.